Jul. 31 at 5:00 PM
$LXRX +
$NVO
ABC News reports the VA is running a major
trial using GLP‑1 drugs to treat alcohol-use
disorder — showing GLP‑1s don’t just curb
appetite, they modulate reward circuits and
compulsive drive.
This is quietly bullish for LXRX.
As GLP‑1s expand beyond weight loss into
addiction therapy, exposure rises — and so
do catabolic side effects like rapid fat-pad
loss and lean-mass depletion.
That’s where LX9851 + ACSL blockade fits.
ACSL blockers modulate lipid flux, preserve
lean mass, and protect structural fat
compartments. If GLP‑1s become a multi-
indication platform (obesity, diabetes,
addiction), LX9851 becomes a companion
therapy that improves tolerability and
broadens use.
Novo Nordisk is already partnered with LXRX.
GLP‑1 expansion = LX9851 opportunity.
$BIB $VTRS
https://www.foxnews.com/video/6402530344112
https://www.militarytimes.com/veterans/2026/07/30/va-launches-trial-to-test-glp-1-medication-for-alcohol-use-disorder-in-veterans/
